Core Viewpoint - Evercore ISI has raised Apple's target price from $250 to $260 while maintaining an "Outperform" rating [1] Summary by Category - **Target Price Adjustment** - The target price for Apple has been increased to $260 from the previous $250 [1] - **Rating Status** - Evercore ISI continues to rate Apple as "Outperform" [1]

Group 1 - UBS raised Oracle's target price from $280 to $360 [1]

Group 1 - Truist Securities raised the target price for UnitedHealth Group (UNH.US) from $310 to $365 [1]

Group 1 - Wells Fargo raised the target price for Broadcom (AVGO.US) from $255 to $345 [1]

Group 1 - Barclays raised the target price for Macy's from $12 to $15 while maintaining a "hold" rating [1]

Group 1 - Barclays analyst Andrew Mok raised the target price for Cigna Group from $354 to $383, maintaining an "overweight" rating [1] - The new target price implies a 27% upside from the company's latest stock price [1]

Group 1 - Truist Securities raised the target price for Citigroup from $99 to $105, maintaining a "Buy" rating [1]

Group 1 - Rosenblatt Securities raised the target price for Alphabet (GOOGL.US) from $191 to $224 [1]

Group 1 - Goldman Sachs has lowered the sales forecast for China National Pharmaceutical Group (03933) for the years 2023 to 2027 by 17.7% to 17.8% [1] - The earnings forecast has been reduced by 28.4% to 35.6% [1] - The firm expects a weak price cycle for antibiotic active pharmaceutical ingredients over the next two years [1] Group 2 - The sales of the company in the first half of the year increased by 5% year-on-year to 7.5 billion RMB [1] - Core business revenue decreased by 15% year-on-year to 6.1 billion RMB, which was below the firm's expectation of 6.5 billion RMB [1] - Profit increased by 27% year-on-year to 1.9 billion RMB, but core profit declined and was below the firm's expectations [1] Group 3 - The firm has raised the target price for the stock from 15.29 HKD to 16.07 HKD, maintaining a "neutral" rating [1] - The sales forecast for high-margin insulin products has been increased by 27% to 30%, benefiting from incremental sales due to exports [1] - The company's gross margin for intermediates and bulk pharmaceuticals has been eroded, and increased administrative expenses due to business expansion consulting fees have been noted [1]

Group 1 - Investment bank Citizens raised Google's target price from $225 to $250 [1]